Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52 GBX | 0.00% | 0.00% | +0.97% |
23/04 | Cambridge Cognition partly-owned spin-off gets GBP1.5 million funding | AN |
23/04 | Cambridge Cognition's Spin-Out Company Closes Fundraise for Schizophrenia Drug | MT |
Sales 2023 * | 13.5M 16.86M 1.41B | Sales 2024 * | 16M 19.98M 1.67B | Capitalization | 16.17M 20.19M 1.68B |
---|---|---|---|---|---|
Net income 2023 * | -3M -3.75M -312M | Net income 2024 * | - 0 0 | EV / Sales 2023 * | 1.18 x |
Net cash position 2023 * | 200K 250K 20.83M | Net cash position 2024 * | 150K 187K 15.62M | EV / Sales 2024 * | 1 x |
P/E ratio 2023 * |
-5.15
x | P/E ratio 2024 * |
-37.4
x | Employees | 80 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 71.79% |
Current month | -7.47% | ||
1 month | -5.45% | ||
3 months | +5.05% | ||
6 months | -27.78% | ||
Current year | +0.97% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Stork
CEO | Chief Executive Officer | 55 | 12/19/12 |
Stephen Symonds
DFI | Director of Finance/CFO | 50 | 06/22/06 |
Steven Powell
CHM | Chairman | 63 | 06/15/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Bungay
BRD | Director/Board Member | 55 | 14/20/14 |
Stuart Gall
BRD | Director/Board Member | 62 | 01/02 |
Steven Powell
CHM | Chairman | 63 | 06/15/06 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 52 | 0.00% | 4,800 |
25/24/25 | 52 | 0.00% | 3,759 |
24/24/24 | 52 | 0.00% | 30,351 |
23/24/23 | 52 | 0.00% | 49,034 |
22/24/22 | 52 | 0.00% | 0 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.97% | 20.14M | |
-20.09% | 26.53B | |
+1.38% | 9.32B | |
-6.43% | 4.6B | |
-25.68% | 729M | |
-1.92% | 479M | |
-9.71% | 448M | |
-28.88% | 210M | |
-42.63% | 189M | |
-6.34% | 152M |
- Stock Market
- Equities
- COG Stock